High response rates for stage 1-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (Zevalin)

被引：0
|
作者：
Samaniego, F. [1 ]
Pro, B. [1 ]
Nunez, R. [1 ]
McLaughlin, P. [1 ]
Fanale, M. [1 ]
Kwak, L. [1 ]
Romaguera, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [21] Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
    Storto, G.
    Nardelli, A.
    Pellegrino, T.
    Perna, F.
    De Falco, T.
    Erra, P.
    Ortosecco, G.
    Castaldi, E.
    Speranza, A.
    Klain, M.
    De Renzo, A.
    di Nuzzo, C.
    Pace, L.
    Rotoli, B.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [22] Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
    Tobinai, Kensei
    Watanabe, Takashi
    Ogura, Michinori
    Morishima, Yasuo
    Hotta, Tomomitsu
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Okamoto, Shin-ichiro
    Taniwaki, Masafumi
    Tsukamoto, Norifumi
    Okumura, Hirokazu
    Terauchi, Takashi
    Nawano, Shigeru
    Matsusako, Masaki
    Matsuno, Yoshihiro
    Nakamura, Shigeo
    Mori, Shigeo
    Ohashi, Yasuo
    Hayashi, Masaki
    Endo, Keigo
    CANCER SCIENCE, 2009, 100 (01) : 158 - 164
  • [23] A phase II trial of CHOP chemotherapy followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL)
    Zinzani, PL
    Tani, M
    Stefoni, V
    Alinari, L
    Marchi, E
    Fina, M
    Baccarani, M
    BLOOD, 2005, 106 (11) : 271B - 271B
  • [24] Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma
    Alcindor T.
    Witzig T.E.
    Current Treatment Options in Oncology, 2002, 3 (4) : 275 - 282
  • [25] Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
    Kim, Moon Jin
    Lee, Gyeong-Won
    Seo, Jong Woo
    Kim, Hyun-Jung
    Lim, Sung-Nam
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1098 - 1101
  • [26] Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant
    Arnason, Jon E.
    Luptakova, Katarina
    Rosenblatt, Jacalyn
    Tzachanis, Dimitrios
    Avigan, David
    Zwicker, Jeffrey I.
    Levine, James
    Kim, Michelle
    Parker, J. Anthony
    Grant, Barbara
    Joyce, Robin M.
    ACTA HAEMATOLOGICA, 2015, 133 (04) : 347 - 353
  • [27] Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
    Moon Jin Kim
    Gyeong-Won Lee
    Jong Woo Seo
    Hyun-Jung Kim
    Sung-Nam Lim
    Cheolwon Suh
    Investigational New Drugs, 2011, 29 : 1098 - 1101
  • [28] Yttrium-90-labeled ibritumomab tiuxetan (Zevalin®) for primary CNS lymphoma -: Final results of a phase II study
    Kiewe, P.
    Korfel, A.
    Maza, S.
    Jahnke, K.
    Munz, D. L.
    Thiel, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 87 - 88
  • [29] Results of the first-line indolent trial of Yttrium-90 ibritumomab tiuxetan consolidation therapy in responsive patients with advanced-stage follicular lymphoma
    Muneer, Sabeeha
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 15 - 17
  • [30] Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: an open-label pilot study
    Steinhoff, M.
    Maza, M.
    Gellrich, S.
    Assaf, C.
    Orawa, H.
    Munz, D.
    Sterry, W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S16 - S16
12345